Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and FLOT in operable gastro-oesophageal adenocarcinoma
NCT03399071Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jul 2017
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of avelumab in gastric adenocarcinoma, oesophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Royal Marsden NHS Foundation Trust. Status: unknown.
02
Drugs
avelumab
03
Conditions
gastric adenocarcinomaoesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03399071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399071.